Merck - 63 Year Stock Price History | MRK

Historical daily share price chart and data for Merck since 1962 adjusted for splits and dividends. The latest closing stock price for Merck as of April 09, 2025 is 81.91.
  • The all-time high Merck stock closing price was 129.91 on June 24, 2024.
  • The Merck 52-week high stock price is 134.63, which is 64.4% above the current share price.
  • The Merck 52-week low stock price is 76.00, which is 7.2% below the current share price.
  • The average Merck stock price for the last 52 weeks is 109.84.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2025 91.7347 98.3206 100.1550 78.9500 81.9100 -16.95%
2024 115.4299 109.2870 129.9050 94.7268 98.6279 -6.26%
2023 102.8071 104.3410 111.9110 95.9880 105.2140 1.01%
2022 82.9310 69.9198 105.2610 66.8636 104.1620 49.42%
2021 67.7374 67.8048 81.5799 60.4431 69.7106 1.75%
2020 66.5447 74.7123 74.7123 54.3446 68.5083 -7.20%
2019 65.7470 59.7320 74.4688 57.6222 73.8274 22.27%
2018 49.9078 43.1044 62.2589 41.1724 60.3800 39.95%
2017 46.8775 44.7459 50.2977 41.1291 43.1427 -1.49%
2016 42.0499 37.8186 47.9561 35.0153 43.7938 15.05%
2015 40.0205 39.8823 43.9549 34.5939 38.0636 -3.89%
2014 39.2339 33.4898 42.8292 33.4898 39.6034 16.93%
2013 30.7740 26.9657 33.8687 26.6460 33.8687 26.83%
2012 26.3406 23.9797 30.9866 23.3598 26.7047 13.14%
2011 20.8210 21.5443 23.7292 18.2237 23.6040 9.56%
2010 21.0305 21.2040 23.5072 18.4214 21.5443 2.91%
2009 16.5325 16.8491 21.7712 11.5997 20.9347 26.70%
2008 19.5984 29.8396 31.4935 12.6229 16.5230 -45.33%
2007 25.9584 22.2168 31.6080 21.6717 30.2245 37.35%
2006 18.9546 15.8785 23.1268 15.8785 22.0048 42.68%
2005 14.4566 14.4177 16.3033 12.3745 15.4228 4.04%
2004 18.9254 20.8996 21.8207 11.8291 14.8236 -27.77%
2003 22.4239 23.7792 26.1649 17.8776 20.5221 -11.20%
2002 21.7420 23.7745 25.7543 15.7246 23.1097 -1.21%
2001 28.0284 36.2852 36.2852 22.7441 23.3926 -35.96%
2000 28.5273 25.9357 36.9680 20.7841 36.5290 41.76%
1999 27.8503 28.2776 32.7319 23.1843 25.7679 -7.49%
1998 24.1264 20.0137 29.9652 19.1305 27.8527 41.30%
1997 17.3897 14.5770 19.9556 14.5770 19.7116 35.65%
1996 12.2867 11.4791 15.2992 10.2344 14.5313 23.94%
1995 8.7312 6.6611 11.9481 6.3563 11.7248 76.60%
1994 5.6908 5.9279 6.8570 4.8139 6.6393 14.85%
1993 5.8047 7.1601 7.1601 4.7529 5.7808 -18.33%
1992 7.8376 8.8763 9.0097 6.6747 7.0786 -20.31%
1991 6.3366 4.6830 8.8830 4.3037 8.8830 88.89%
1990 4.0799 4.0110 4.7027 3.4466 4.7027 18.95%
1989 3.5510 2.8507 4.0578 2.8507 3.9536 37.49%
1988 2.6907 2.6640 2.9429 2.3581 2.8756 11.95%
1987 2.7014 2.0102 3.5083 2.0102 2.5687 29.98%
1986 1.5103 1.0783 2.0660 1.0578 1.9763 84.61%
1985 0.8455 0.7065 1.0705 0.6857 1.0705 50.10%
1984 0.6595 0.6622 0.7165 0.5943 0.7132 7.70%
1983 0.6559 0.5965 0.7581 0.5823 0.6622 10.20%
1982 0.5354 0.5851 0.6231 0.4480 0.6009 3.62%
1981 0.5850 0.5710 0.6894 0.5192 0.5799 3.08%
1980 0.4748 0.4543 0.5626 0.3808 0.5626 21.28%
1979 0.4267 0.4232 0.4728 0.3963 0.4639 10.03%
1978 0.3535 0.3244 0.4309 0.2935 0.4216 25.59%
1977 0.3346 0.3941 0.3941 0.2983 0.3357 -16.22%
1976 0.4159 0.4010 0.4701 0.3706 0.4007 0.45%
1975 0.4248 0.3803 0.4879 0.3323 0.3989 6.26%
1974 0.4037 0.4480 0.4815 0.2771 0.3754 -16.58%
1973 0.4937 0.4972 0.5539 0.4315 0.4500 -8.09%
1972 0.4174 0.3402 0.4910 0.3402 0.4896 45.37%
1971 0.2850 0.2528 0.3551 0.2528 0.3368 27.87%
1970 0.2441 0.2906 0.2932 0.1948 0.2634 -10.77%
1969 0.2466 0.2361 0.2978 0.2162 0.2952 25.56%
1968 0.2225 0.2116 0.2482 0.1927 0.2351 6.67%
1967 0.2167 0.1966 0.2452 0.1946 0.2204 9.93%
1966 0.1930 0.1874 0.2109 0.1701 0.2005 8.85%
1965 0.1530 0.1267 0.1946 0.1267 0.1842 42.13%
1964 0.1071 0.0961 0.1296 0.0901 0.1296 35.99%
1963 0.0813 0.0678 0.0955 0.0678 0.0953 40.98%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $230.880B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $835.717B 67.80
Novo Nordisk (NVO) Denmark $406.526B 27.53
Johnson & Johnson (JNJ) United States $394.223B 16.39
AbbVie (ABBV) United States $360.274B 20.17
Roche Holding AG (RHHBY) Switzerland $264.748B 0.00
Novartis AG (NVS) Switzerland $223.246B 13.98
Pfizer (PFE) United States $151.025B 8.57
Sanofi (SNY) $136.409B 12.92
Bayer (BAYRY) Germany $23.028B 3.69
Innoviva (INVA) United States $1.132B 9.42